<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5976">
  <stage>Registered</stage>
  <submitdate>4/09/2013</submitdate>
  <approvaldate>4/09/2013</approvaldate>
  <nctid>NCT01937325</nctid>
  <trial_identification>
    <studytitle>CPET in CF Patients With One G551D Mutation Taking VX770</studytitle>
    <scientifictitle>Airway Infection, Inflammatory Markers and Exercise Capacity in Patients With Cystic Fibrosis and at Least One G551D Mutation Taking VX770 (Ivacaftor)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CPET in CF</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ivacaftor
Treatment: drugs - placebo

Active Comparator: Ivacaftor - 150mg orally twice daily

Placebo Comparator: Placebo - Matching placebo


Treatment: drugs: ivacaftor
active arm

Treatment: drugs: placebo
active arm

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>exercise capacity - Respiratory exercise testing, including spirometry and V02 max.</outcome>
      <timepoint>one month, 3 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Inflammatory profile - Cytokine levels (IL-1ÃŸ, IL-6, TNFa, IL-8, VEGF &amp; Activin A) determined using cytometric bead analysis and / or ELISA</outcome>
      <timepoint>One month, 3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  All participants will have CF proven based on established criteria (sweat test,
             genotype and phenotype).

          -  All participants will have at least one copy of the G551D mutation.

          -  All will be able to perform an exercise study and complete study questionnaires and
             assessments.

          -  Age range will be between 16 and 75 years of age.

          -  Lung function inclusion will be above 25% predicted FEV1.</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Participants will not be included if they are unable to complete study assessments or
             have had a known adverse reaction to Ivacaftor.

          -  Female participants will be excluded if found to return a positive pregnancy test at
             screening.

          -  Participants will be excluded if using St. John's Wort or rifampicin (strong CYP3A
             inducers).

          -  Participants with significant liver dysfunction will be excluded (ALT or ALT above 5
             times upper limit of normal).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Basic Science</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2016</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Alfred - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The Alfred</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Ivacaftor will restore CFTR function in treated CF patients with the G551D mutation.
      Improvement in ventilation, salt balance and well-being will contribute to better exercise
      capacity at all levels of lung function. While potential improvements may be variable across
      the spectrum of lung function, even small gains at low levels of FEV1 may have significant
      benefit for some subjects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01937325</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>John Wilson</name>
      <address>Alfred Health and Monash University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>